Imunon, Inc.

NasdaqCM:IMNN Stock Report

Market Cap: US$7.5m

Imunon Management

Management criteria checks 2/4

Imunon's CEO is Stacy Lindborg, appointed in May 2024, has a tenure of 2.17 years. total yearly compensation is $1.03M, comprised of 55.2% salary and 44.8% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $13.91K. The average tenure of the management team and the board of directors is 1.8 years and 8 years respectively.

Key information

Stacy Lindborg

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage55.19%
CEO tenure2.2yrs
CEO ownership0.2%
Management average tenure1.8yrs
Board average tenure8yrs

Recent management updates

Recent updates

Narrative Update • Jun 26

IMNN: Bullish View Will Hinge On Pivotal Ovarian Cancer Survival Data

Analysts have revised their Imunon fair value estimate from $21.50 to $17.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E following recent bullish coverage initiation on the stock. What's in the News An Independent Data Monitoring Committee recommends continuation of Imunon’s pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in combination with standard neoadjuvant and adjuvant chemotherapy in newly diagnosed advanced ovarian cancer patients, with overall survival as the primary endpoint.
New Narrative • Mar 19

Frontline Ovarian Cancer Trial Success Will Transform Long Term Potential For This IL 12 Therapy

Catalysts About Imunon Imunon is a clinical stage biotechnology company focused on developing IMNN-001, an IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 05

Phase III Ovarian Cancer Trial And IL-12 Focus Will Reshape This Long-Term Thesis

Catalysts About Imunon Imunon is a clinical stage biotechnology company developing IMNN-001, an intraperitoneal IL-12 based immunotherapy for women with newly diagnosed advanced ovarian cancer. What are the underlying business or industry changes driving this perspective?

CEO Compensation Analysis

How has Stacy Lindborg's remuneration changed compared to Imunon's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$15m

Dec 31 2025US$1mUS$568k

-US$14m

Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

-US$16m

Mar 31 2025n/an/a

-US$18m

Dec 31 2024US$1mUS$342k

-US$19m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$44kn/a

-US$20m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$55kn/a

-US$36m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$26m

Mar 31 2022n/an/a

-US$26m

Dec 31 2021US$63kn/a

-US$21m

Compensation vs Market: Stacy's total compensation ($USD1.03M) is above average for companies of similar size in the US market ($USD649.34K).

Compensation vs Earnings: Stacy's compensation has been consistent with company performance over the past year.

CEO

Stacy Lindborg (55 yo)

2.2yrs
Tenure
US$1,029,349
Compensation

Dr. Stacy R. Lindborg, Ph D., was Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since January 2023 until May 09, 2024 and serves as its Director since May 09, 2024. Dr. Lindborg joined th...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Tardugno
Executive Chairman19.5yrsUS$605.90k0.53%
$ 39.3k
Stacy Lindborg
President2.2yrsUS$1.03m0.19%
$ 13.9k
Douglas Faller
Chief Medical Officer1.4yrsUS$636.33kno data
Jeffrey Church
Interim Chief Financial Officerless than a yearUS$807.99k0.00062%
$ 46.4
Susan Eylward
General Counsel & Corporate Secretary1.8yrsno data0%
$ 0
Kristin Longobardi
Senior Vice President of Strategic Operations1.8yrsno datano data
1.8yrs
Average Tenure
69yo
Average Age

Experienced Management: IMNN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Michael Tardugno
Executive Chairman19.5yrsUS$605.90k0.53%
$ 39.3k
Stacy Lindborg
President5.1yrsUS$1.03m0.19%
$ 13.9k
Donald Braun
Independent Director10.6yrsUS$61.49k0.22%
$ 16.6k
Wafik El-Deiry
Member of Advisory Boardno datano datano data
David Cheresh
Member of Advisory Boardno datano datano data
Michael Weinblatt
Member of Advisory Boardno datano datano data
James Dentzer
Independent Director3.8yrsUS$85.97k0.36%
$ 26.6k
Frederick Fritz
Independent Director15yrsUS$84.04k0.34%
$ 25.1k
Jerry Glickson
Member of Advisory Boardno datano datano data
Mark Dewhirst
Member of Advisory Boardno datano datano data
Peter Corry
Member of Advisory Boardno datano datano data
Britt Glaunsinger
Member of the Advisory Board5.4yrsno datano data
8.0yrs
Average Tenure
75yo
Average Age

Experienced Board: IMNN's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/01 01:40
End of Day Share Price 2026/07/01 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imunon, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets